SeaGen builds cancer drug pipeline with China biotech deal

SeaGen will add an experimental antibody drug to its expanding pipeline of cancer medicines, announcing Monday a deal with RemeGen to license a treatment the Chinese biotech company is developing for breast, bladder and stomach tumors.